JDRF JDRF

JDRF-funded studies show regular CGM use increases diabetes control for all age groups

NEW YORK, September 8, 2009 -- The latest data from groundbreaking human clinical trials of the effectiveness of continuous glucose monitors (CGM) show that the primary determinant of improvements in achieving better diabetes control is regular use of monitors -- six days per week or more -- rather than the age of patients, and that benefits continue well past the time when people with type

Noninsulin-producing alpha cells in the pancreas can be converted to insulin-producing beta cells

New York, NY, August 6, 2009 -- In findings that add to the prospects of regenerating insulin-producing cells in people with type 1 diabetes, researchers in Europe -- co-funded by the Juvenile Diabetes Research Foundation -- have shown that insulin-producing beta cells can be derived from non-insulin-producing cells in the pancreas.

Study shows CGM devices also benefit people with type 1 diabetes

NEW YORK, May 27, 2009 ? People with type 1 diabetes who have already been successful in achieving recommended blood sugar goals can further benefit from using continuous glucose monitoring (CGM) devices, according to results of a major multi-center clinical trial by the Juvenile Diabetes Research Foundation.

Compounds that trigger beta cell replication identified by JDRF funded researchers

Researchers at the Genomics Institute of the Novartis Research Foundation (GNF) have identified a set of compounds that can trigger the proliferation of insulin-producing cells in the pancreas, using sophisticated high-throughput screening techniques.

1 comment
Read more
554 reads

JDRF-funded studies show regular CGM use increases diabetes control for all age groups

Noninsulin-producing alpha cells in the pancreas can be converted to insulin-producing beta cells

Study shows CGM devices also benefit people with type 1 diabetes

Compounds that trigger beta cell replication identified by JDRF funded researchers

About us

Recommended